NCT07627464Not yet recruitingPhase 2
A Multicenter, Randomized Controlled Phase II Study of Neoadjuvant Anlotinib Hydrochloride Capsules Combined With Benmelstobart Injection Versus Surgery Alone for Localized Renal Cell Carcinoma Planned for Partial Nephrectomy
Tianjin Medical University Cancer Institute and Hospital14 sites in 1 country144 target enrollmentStarted: May 31, 2026Last updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Enrollment
- 144
- Locations
- 14
Study Overview
Brief Summary
Evaluation of long-term renal function improvement, surgical safety, as well as efficacy and safety of preoperative anlotinib hydrochloride capsules combined with benmelstobart injection versus surgery in patients with localized renal cell carcinoma undergoing partial nephrectomy
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Aged between 18 and 75 years, inclusive.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Subjects with newly diagnosed cT1bN0M0 renal cell carcinoma (RCC) scheduled to undergo partial nephrectomy.
- •Have at least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.
- •No prior systemic therapy for renal cell carcinoma, including but not limited to targeted therapy, immunotherapy, investigational therapy, or hormone therapy.
Exclusion Criteria
- •Subjects with a solitary kidney tumor.
- •Subjects with bilateral renal tumors or unilateral multiple renal tumors (n ≥ 2).
- •Subjects with hereditary or familial renal tumors (e.g., von Hippel-Lindau [VHL] disease).
- •Subjects with a prior history of renal transplantation.
Investigators
Study Sites (14)
Loading locations...
Similar Trials
Not yet recruiting
Phase 1
A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal ImpairmentNCT07445906Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.24
Not yet recruiting
Phase 3
A study evaluating the sleep improving effects and safety of Suvorexant in comparison to Lemborexant in participants with Insomnia.CTRI/2026/02/102974Sun Pharmaceutical Industries Limited (SPIL)410
Recruiting
Phase 3
A multicenter randomized trial to evaluate the efficacy of pioglitazone to improve renal outcome in ANCA-associated vasculitis - RENATO2022-501057-36-00Assistance Publique Hopitaux De Paris126
Recruiting
Phase 2
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionNCT07327034Abbisko Therapeutics Co, Ltd141
Recruiting
Not Applicable
Single-Needle Distal Return for Long-Term Arteriovenous Fistula CareArteriovenous FistulaNCT07372027Suzhou Municipal Hospital of Anhui Province100